Using Mouse Models to Study the Role of Ubiquilin-1 in Alzheimer’s Disease

About the Research Project
Program
Award Type
Standard
Award Amount
$250,000
Active Dates
July 01, 2014 - June 30, 2017
Grant ID
A2014420S
Goals
A protein named ubiquilin-1 has long been considered to play a role in Alzheimer’s disease. However, the exact role of the protein in Alzheimer’s disease remains unclear. This research project is to investigate whether increase or depletion of the ubiquilin-1 protein in genetically modified mice changes the signs and conditions of Alzheimer’s disease.
Summary
The goal of this project is to determine whether the onset and progression of Alzheimer’s disease (AD) in mice can be altered by the manipulation of a protein called ubiquilin-1. One major manifestation of AD is the accumulation of unwanted amyloid proteins in brain tissues. Previous studies conducted by these scientists have indicated that the ubiquilin-1 protein helps cell remove unwanted proteins; therefore, ubiquilin-1 may play a protective role for nerve cells affected by AD.
Dr. Wang’s group has produced genetically modified mice that either express excessive levels of ubiquilin-1 or are deficient in their expression of that protein. The scientists are currently crossing these mice with an AD mouse model, a group of mice whose specific genetic makeup allows them to serve as a model for the conditions of AD in humans. This crossbreeding will produce mice that exhibit the features of both original groups; the offspring will be AD mice that either express excessive ubiquilin-1 or lack the protein expression. Dr. Wang’s team will then investigate whether increasing or decreasing of ubiquilin-1 protein levels alters AD symptoms and progression, brain tissue structures, or the breakdown of the major AD-related proteins in the animals. The results of this study will help Dr. Wang’s team determine whether ubiquilin-1 affects the onset and progression of AD and whether the protein is a target for designing drugs to treat AD.
Related Grants
Alzheimer's Disease Research
Mechanisms of Inhibitory Neuron Vulnerability to Alzheimer’s Disease
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Emiliano Zamponi, PhD
Current Organization
Columbia University
Alzheimer's Disease Research
Targeting Brain Cell Miscommunication to Restore Memory in Alzheimer’s Disease
Active Dates
July 01, 2024 - June 30, 2027

Principal Investigator
Amira Latif-Hernandez, PhD
Current Organization
Stanford University
Alzheimer's Disease Research
Progranulin as a Potential Therapeutic Target for Alzheimer's Disease
Active Dates
July 01, 2024 - June 30, 2027

Principal Investigator
Andrew Nguyen, PhD
Current Organization
Saint Louis University